Medical Marijuana Testing Advisory Council September 26, 2019 - - PowerPoint PPT Presentation

medical marijuana testing advisory council
SMART_READER_LITE
LIVE PREVIEW

Medical Marijuana Testing Advisory Council September 26, 2019 - - PowerPoint PPT Presentation

Medical Marijuana Testing Advisory Council September 26, 2019 Councils Charge A.R.S. 362821(B) The MMJ Testing Advisory Council shall make recommendationsregarding: Establishing a required testing program Testing and potency


slide-1
SLIDE 1

Medical Marijuana Testing Advisory Council

September 26, 2019

slide-2
SLIDE 2

Council’s Charge

slide-3
SLIDE 3

A.R.S. §36‐2821(B)

The MMJ Testing Advisory Council shall make recommendations…regarding:

  • Establishing a required testing program
  • Testing and potency standards
  • Procedural requirements for collection, storing,

and testing

  • Reporting results to patients and the department
  • Remediation and disposal requirements
slide-4
SLIDE 4

Open Meeting Law

slide-5
SLIDE 5

Open Meeting Law

  • Ensure completion of training and oath
slide-6
SLIDE 6

What is Open Meeting Law and why do we have it?

A.R.S. § 38‐431.01(A), § 38‐431.09

  • Protect and inform the public
  • Maintain integrity of government
  • Build trust between government and citizens
  • Arizona’s public policy requires that official

deliberations and proceedings be conducted

  • penly
  • Any uncertainty should be resolved in favor of
  • pen and public meetings
slide-7
SLIDE 7

What is a meeting?

A.R.S. § 38‐431(4) Means the gathering, in person or through technological devices of a quorum of the members of a public body at which the discuss, propose or take legal action, including any deliberations by a quorum with respect to that

  • action. Includes:
  • A one way electronic communication by one member
  • f a public body that is sent to a quorum of the

members of a public body that proposes legal action.

  • An exchange of electronic communications among a

quorum of the members of a public body that involves a discussion, deliberation or the taking of legal action by the public body concerning a matter likely to come before the public body for action.

slide-8
SLIDE 8

Discuss, Propose, or Take Legal Action

  • Normal use and meaning of these words will

apply.

  • Proposing legal action = “put forward for

consideration, discussion, or adoption.”

  • Includes deliberations = discussion of facts

and opinions re: potential board business.

  • RULE: If this occurs among a quorum of the

Board IT IS A MEETING.

slide-9
SLIDE 9

If it’s NOT on the agenda

  • If it’s NOT on the Agenda, it CANNOT be

discussed.

  • All discussion must be reasonably related to

an adequately described agenda item.

  • If something else is brought up, add it to the

agenda of a future meeting and discuss it then.

slide-10
SLIDE 10

Avoiding Open Meeting Law Violations

  • DO NOT discuss, propose, deliberate or take

legal action on any potential Council business among a quorum of the Council outside a properly noticed public meeting.

  • Council business includes anything that may

foreseeably come before the Council for action.

slide-11
SLIDE 11

Circumvention

  • Cannot have meetings with less than a

majority or use any device to circumvent the law

  • Meeting with individual members
  • Reporting what other members said
  • Polling the members
slide-12
SLIDE 12

AG Opinion on Email

  • No. I05‐004 (R05‐010)
  • Re: Open Meeting Law Requirements and

E‐mail to and from Members of a Public Body

  • Issued July 25, 2005
  • Available: www.azag.gov
slide-13
SLIDE 13

AG Opinion on Email

  • E‐mail communications among a quorum of a public body

are subject to the same restrictions that apply to all other forms of communication among a quorum.

  • E‐mails among a quorum that involve discussions,

deliberations or taking legal action on matters that may reasonably be expected to come before the board constitute a meeting through technological means.

  • One‐way e‐mail communication by one member to

quorum of members that proposes legal action is a violation even if there is no discussion, deliberation or legal action taken.

slide-14
SLIDE 14

Violations and Sanctions

  • Actions are null and void

(A.R.S. § 38‐431.05)

  • May face civil penalties, attorney’s fees or removal from
  • ffice. ( A.R.S. § 38‐431.07)
slide-15
SLIDE 15

Overview of testing‐related components of statute and rule

slide-16
SLIDE 16

A.R.S. §36‐2803

  • A.R.S. §36‐2803(E) – Test
  • A.R.S. §36‐2803(F) – Provide results
  • A.R.S. §36‐2803(G) – Meet requirements

– QA program – Chain of custody policies – Records retention – Valid and scientifically accurate results – Be accredited – Disposal policies

slide-17
SLIDE 17

A.R.S. §36‐2804.07

  • Independent third party laboratories shall be

certified by the department

  • Certified independent third party laboratories

are subject to reasonable inspection by the department

slide-18
SLIDE 18

9 A.A.C. 17 Article 4

  • Application for laboratory registration

certificate

  • Administration
  • Registry identification cards
  • Inventory control
  • Security
  • Physical plant
slide-19
SLIDE 19

Tentative Meeting Plans

  • 9/26/19:

– review of testing and potency standards

  • 10/24/19:

– recommendation on testing and potency standards – review of sample collection & storage, reporting results, remediation, disposal

  • 11/12/19

– recommendation on sample collection & storage, reporting results, remediation, disposal

  • 12/10/19

– final recommendation report

slide-20
SLIDE 20
slide-21
SLIDE 21

ADHS’ Information Gathering

  • Names and locations of current labs and

visited 9

  • Information from labs and states on which

states had best programs

  • 50 states’ regulations search
  • Technical journal and industry article

review

  • Conference calls with MI and MD.
  • Visited CO program
slide-22
SLIDE 22

Current AZ Laboratories Testing MM

slide-23
SLIDE 23

3 Main Questions to Solve First

1. What parameters are we going to test for in medical marijuana? 2. What are the standards or limits of allowed contamination? 3. How is the medical marijuana being tested?

slide-24
SLIDE 24

A.R.S. § 36‐2803

  • E. “Beginning November 1, 2020, before selling
  • r dispensing marijuana or marijuana products to

registered designated caregivers, nonprofit medical dispensaries shall test marijuana and marijuana products for medical use to determine unsafe levels of microbial contamination, heavy metals, pesticides, herbicides, fungicides, growth regulators and residual solvents and confirm the potency of the marijuana to be dispensed.”

slide-25
SLIDE 25

A.R.S. § 36‐2803

  • F. … “An Independent third‐party laboratory:

  • 6. Must establish procedures to ensure that

results are accurate, precise and scientifically valid before reporting the results.”

slide-26
SLIDE 26
slide-27
SLIDE 27

AHP (2014)

slide-28
SLIDE 28

Microbial Contamination

slide-29
SLIDE 29

A.R.S. § 36‐2803

  • E. “Beginning November 1, 2020, before selling
  • r dispensing marijuana or marijuana products to

registered designated caregivers, nonprofit medical dispensaries shall test marijuana and marijuana products for medical use to determine unsafe levels of microbial contamination, heavy metals, pesticides, herbicides, fungicides, growth regulators and residual solvents and confirm the potency of the marijuana to be dispensed.”

slide-30
SLIDE 30

AHP Microbial Contamination

slide-31
SLIDE 31
slide-32
SLIDE 32

50 State Review

slide-33
SLIDE 33
slide-34
SLIDE 34
slide-35
SLIDE 35
slide-36
SLIDE 36
slide-37
SLIDE 37
slide-38
SLIDE 38

Number of States Using Each E. coli Limit

slide-39
SLIDE 39

Microbial Contamination Standards for Consideration:

  • All Medical Marijuana products tested for E. coli using methods

from the Bacteriological Analytical Manual (FDA 2013a).

  • <1 CFU/g, it can be released for retail sale.
  • Unless Aspergillus testing required also for inhalables.
  • 1‐10 CFU/g, it must be tested for the presence of E. coli (STEC)

and Salmonella species. If they are detected, the product can not be released for retail sale.

  • >10 CFU/g can not be released for retail sale.
  • If a plant product tests >10 CFU/g, but is non‐detect for

the presence of E. coli (STEC) and Salmonella species, it can be remediated for extracted products for retail sale.

  • If the test batch is found to contain levels of any microbial that

could be toxic if consumed, then the department may determine that the test batch has failed contaminant testing.

slide-40
SLIDE 40

Microbial Contamination Considerations: ‐Aspergillus species? (2 options):

  • 1. All medical marijuana plant inhalables shall be

tested for the presence of Aspergillus flavus, Aspergillus fumigatus, Aspergillus niger and Aspergillus terreus. If any of these are detected in 1 gram of a product, it can not be released for retail sale.

  • r
  • 2. All inhalable plant products shall be labeled to

include a warning about the risk from inhaling mold for people with suppressed immune systems.

slide-41
SLIDE 41

Heavy Metals

slide-42
SLIDE 42

A.R.S. § 36‐2803

  • E. “Beginning November 1, 2020, before selling
  • r dispensing marijuana or marijuana products to

registered designated caregivers, nonprofit medical dispensaries shall test marijuana and marijuana products for medical use to determine unsafe levels of microbial contamination, heavy metals, pesticides, herbicides, fungicides, growth regulators and residual solvents and confirm the potency of the marijuana to be dispensed.”

slide-43
SLIDE 43

AHP Heavy Metals

slide-44
SLIDE 44

Testing of Chromium?

  • 2 States see a lot of chromium failures in

flower, mainly from trimming.

  • Harmful forms of chromium can be found

in pigments, fungicides and corrosion inhibitors.

slide-45
SLIDE 45

50 State Review

slide-46
SLIDE 46

Michigan Heavy Metals Limits

slide-47
SLIDE 47
slide-48
SLIDE 48
slide-49
SLIDE 49
slide-50
SLIDE 50

MA Regulations

slide-51
SLIDE 51

Heavy Metals Considerations:

  • Test for arsenic, cadmium, lead, mercury and

chromium.

  • Adopt USP limits for arsenic, cadmium, lead and

mercury and MI limits for chromium.

  • Adopt FDA and USP validated methods possibly

with EPA Method support.

  • If test batch is found to contain levels of any

heavy metal that could be toxic if consumed, then the Department may determine that the test batch has failed contaminant testing.

slide-52
SLIDE 52

Pesticides, Herbicides, Fungicides, Growth Regulators

slide-53
SLIDE 53

A.R.S. § 36‐2803

  • E. “Beginning November 1, 2020, before selling
  • r dispensing marijuana or marijuana products to

registered designated caregivers, nonprofit medical dispensaries shall test marijuana and marijuana products for medical use to determine unsafe levels of microbial contamination, heavy metals, pesticides, herbicides, fungicides, growth regulators and residual solvents and confirm the potency of the marijuana to be dispensed.”

slide-54
SLIDE 54

AHP Pesticides, Fungicides and Growth Regulators

No herbicides In AHP.

slide-55
SLIDE 55

List of Herbicides Approved for Use in Vegetables UofA 2011

slide-56
SLIDE 56
slide-57
SLIDE 57

USEPA

slide-58
SLIDE 58

2015

slide-59
SLIDE 59
slide-60
SLIDE 60
slide-61
SLIDE 61

Compiled State Pesticide, Fungicide, Growth Regulator, Herbicide Lists and Standards

slide-62
SLIDE 62
slide-63
SLIDE 63
slide-64
SLIDE 64

LC‐MS/MS And GC/MS

slide-65
SLIDE 65
slide-66
SLIDE 66
slide-67
SLIDE 67

MA Regulations

slide-68
SLIDE 68

Pesticide, Fungicide, Herbicide and Growth Regulator Considerations:

  • Adopt the 2015 Oregon list and safety limits initially

until further info is obtained for Arizona samples.

  • Adopt AOAC validated GC/MS and LC‐MS/MS methods

possibly with EPA Method support.

  • Test the AOAC methods to see if herbicides can be

added.

  • If testing identifies the use of a banned pesticide or the

improper application of a permitted pesticide, then that test batch shall be considered to have failed contaminant testing.

slide-69
SLIDE 69

Residual Solvents

slide-70
SLIDE 70

A.R.S. § 36‐2803

  • E. “Beginning November 1, 2020, before selling
  • r dispensing marijuana or marijuana products to

registered designated caregivers, nonprofit medical dispensaries shall test marijuana and marijuana products for medical use to determine unsafe levels of microbial contamination, heavy metals, pesticides, herbicides, fungicides, growth regulators and residual solvents and confirm the potency of the marijuana to be dispensed.”

slide-71
SLIDE 71

AHP Residual Solvents

slide-72
SLIDE 72

50 State Review

slide-73
SLIDE 73

2015

slide-74
SLIDE 74
slide-75
SLIDE 75

USP Method

slide-76
SLIDE 76

Draft AOAC Cannabis Specific Method Criteria

slide-77
SLIDE 77

MA Regulations

Needs 8000D

slide-78
SLIDE 78

Residual Solvents Considerations:

  • Adopt Oregon’s 2015 list and safety limits

initially until further info is obtained for Arizona samples.

  • Adopt USP validated methods with the support

from EPA Methods and AOAC cannabis specific method criteria.

  • If test batch is found to contain levels of any

chemical that could be toxic if consumed, then the Department may determine that the test batch has failed contaminant testing.

slide-79
SLIDE 79

Potency

slide-80
SLIDE 80

A.R.S. § 36‐2803

  • E. “Beginning November 1, 2020, before selling
  • r dispensing marijuana or marijuana products to

registered designated caregivers, nonprofit medical dispensaries shall test marijuana and marijuana products for medical use to determine unsafe levels of microbial contamination, heavy metals, pesticides, herbicides, fungicides, growth regulators and residual solvents and confirm the potency of the marijuana to be dispensed.”

slide-81
SLIDE 81

2 AHP Potency Methods

slide-82
SLIDE 82

Potency Considerations:

  • States’ cannabinoid lists vary widely.
  • Adopt AZ cannabinoid list that includes

the acid forms THCa, CBDa and CBCa.

  • Adopt method criteria for AHP methods

with AOAC and EPA method support.

slide-83
SLIDE 83

One Method Will Probably Not Work For All Matrices

slide-84
SLIDE 84
slide-85
SLIDE 85

Discussion of testing and potency standards

slide-86
SLIDE 86

Next Meeting: October 24, 2019

slide-87
SLIDE 87

Adjourn